CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti,

Bank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6%

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026

Sarepta Therapeutics NASDAQ: SRPT reported second-quarter 2026 total revenue of $401 million, down 3

Sarepta Therapeutics (NASDAQ: SRPT) reported second-quarter 2026 total revenue of $401 million, down

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks C

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the busin

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the ana

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a l

Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael ​Severino i

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sa

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sec

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:

FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a

– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, hea

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and

U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49,

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while T

Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook

In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle

Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes agai

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperf

– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA b

- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Coho

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises t

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

uniQure (QURE) stock surges following news of CBER director Vinay Prasad's exit. See why the mar

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)